SUBSCRIBE
SUBSCRIBE
News   Deals

Sanofi-Aventis (France) Hopes to Win Genzyme Corporation for $76/Share; Said to be Ceiling Price

January 14, 2011 | 
1 min read
(Reuters) - French drugmaker Sanofi-Aventis hopes to reach a takeover deal that would value U.S. target Genzyme (NasdaqGS:GENZ - News) at around $76 per share, or some $20 billion, the French daily newspaper Le Figaro said on Friday.
Mergers & acquisitions Europe
Sanofi
MORE ON THIS TOPIC
Hand collage holding dollar paper money isolated on yellow background. Using cash to buy concept. Halftone effect in pop art style illustration.
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
March 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Business and HR concepts for leaders and teams. Circular wooden blocks with hand icons printed on them are connected to wooden blocks with business people icons printed on them. Teamwork concept, business concept
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
March 19, 2026
 · 
2 min read
 · 
Tristan Manalac
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
In Tight Deal Environment, Pharma May Need To Think Big
March 18, 2026
 · 
5 min read
 · 
Annalee Armstrong
Confrontation and opposite opinions concept. Business people hands pulling rope in opposite directions in office showing power and leadership vector illustration
Mergers & acquisitions
Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles
March 11, 2026
 · 
5 min read
 · 
Annalee Armstrong